-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66

Benzinga·08/13/2026 15:07:38
Listen to the news
RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $66.